|
市场分析报告
|
Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022 ... Hydrolase (FAAH) Inhibitor Features the Fatty Acid Amide Hydrolase (FAAH) Inhibitor pipeline ... Fatty Acid Amide Hydrolase (FAAH) Inhibitor to formulate effective R&D strategies ... Fatty Acid Amide Hydrolase (FAAH) Inhibitor research & development (R&D) Gather ...
Fatty Acid Amide Hydrolase (FAAH) Inhibitor -Pipeline Intelligence, 2019 ... ’s, “Fatty Acid Amide Hydrolase (FAAH) Inhibitor-Pipeline Intelligence, 2019”, report ... Fatty Acid Amide Hydrolase (FAAH) Inhibitor. Pipeline Covered: This section ... Fatty Acid Amide Hydrolase (FAAH) Inhibitor R&D Please note: Certain sections in ...
Infinity Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... fatty acid amide hydrolase (FAAH). Hsp90 Chaperone Inhibitor Program The company is conducting ... of IPI-940, its orally-available inhibitor of FAAH. The Phase 1 program includes single ...
Ironwood Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... stage candidate is IW-6118, an inhibitor of Fatty Acid Amide Hydrolase (FAAH) being evaluated for ...
Cannabinoid Based Drug Discovery And Development Market By Drug Development Stage, By Receptor Target (CB1 Receptor, CB2 Receptor), By End User (Pharmaceutical Companies, Research Institutes, Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2025-2034 ... , Antagonist, and Inverse Agonist), FAAH Inhibitor, MAGL Inhibitor, FAAH-MAGL Dual Inhibitor, and TRPV1 (Agonist ...
2020 Drug Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs ... Receptors agonist; dopamine transporter inhibitor; Dopamine uptake inhibitors; FAAH (Fatty Acid Amide Hydrolase ... ) inhibitor; GABA A receptor agonists; Glucocorticoid receptor ...
2020 Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs ... -CoA synthetase 2 (ACSS2) inhibitor; fatty acid amide hydrolase (FAAH) inhibitor; GABA A receptor agonists ... ; GABA aminotransferase inhibitor; Glucocorticoid receptor antagonist ...
|
|
|